https://www.selleckchem.com/pr....oducts/Temsirolimus.
Our study is the first to show that TDO expression in tumor tissues is associated with progression and survival, confirming its potential as a predictive biomarker of primary resistance to immunotherapy in patients with mRCC. Our findings suggest that strategies aimed at inhibiting TDO, rather than IDO1, in combination with ICI therapy may aid in the control of mRCC progression.Tuberculosis (T is currently the leading cause of death related to infectious diseases worldwide, as reported by the World Health Organization. Moreover,